trending Market Intelligence /marketintelligence/en/news-insights/trending/aewaswju1ntpv-dd43ggqa2 content esgSubNav
In This List

A1M Pharma appoints chief medical officer

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


A1M Pharma appoints chief medical officer

A1M Pharma AB appointed Tobias Larsson Agervald as chief medical officer, effective Dec. 1.

Agervald is a senior medical director in Astellas Pharma Inc.'s Global Clinical Development in the Netherlands. He also co-founded the European Renal Association - European Dialysis and Transplantation Association's endorsed Working Group on Mineral and Bone Disorders.

Sweden-based A1M Pharma is developing ROSgard, based on the protein alpha-1-microglobulin, or A1M, to treat pre-eclampsia, a pregnancy complication characterized by high blood pressure and signs of damage to another organ, most often the liver and kidney, as well as acute kidney injury.